item management s discussion and analysis of financial condition and results of operations this report contains forward looking statements which involve risks and uncertainties 
such statements are subject to certain factors which may cause the company s plans and results to differ significantly from plans and results discussed in forward looking statements 
factors that might cause or contribute to such differences include  but are not limited to  those discussed in important factors regarding forward looking statements attached hereto as exhibit overview since its inception in january  alexion has devoted substantially all of its resources to its drug discovery  research and product development programs 
to date  alexion has not received any revenues from the sale of products 
the company has been unprofitable since inception  and expects to incur substantial and increasing operating losses for the next several years due to expenses associated with product research and development  preclinical and clinical testing  regulatory activities and manufacturing development and scale up 
as of july   the company has incurred a cumulative net loss of million 
the company s plan is to develop and commercialize on its own those product candidates for which the clinical trial and marketing requirements can be funded by the company 
for certain of the company s c inhibitor and apogen products for which greater resources will be required  alexion s strategy is to form corporate partnerships with major pharmaceutical companies for product development and commercialization 
alexion has entered into a strategic alliance with us surgical with respect to the company s unigraft program and with gti novartis with respect to the company s gene transfer technology  and intends to seek additional strategic alliances with major pharmaceutical companies although no assurances can be given that such alliances will be successfully entered into 
the company recognizes research and development revenues when the development expenses are incurred and the related work is performed under the terms of the contracts 
any revenue contingent upon future expenditures by the company is deferred and recognized as the expenditures are incurred 
any revenues contingent upon the achievement of milestones will be recognized when the milestones are achieved 
results of operations years ended july    and the company earned grant  license  and contract research revenues of million  million  and  for the fiscal years ended july    and  respectively 
the increase in fiscal was primarily due to the million of revenues the company received from gti novartis which represented a one time upfront license fee of  and contract research and development revenues of  the increase in fiscal year revenues as compared to fiscal resulted principally from company s revenues received from us surgical of approximately million from a collaborative research and development agreement and the funding of  from the nist s atp grant 
the revenues in fiscal resulted from the receipt of funds from two sbir grants from the nih 
see item business strategic alliances  collaborations and licenses 
during the fiscal years ended july    and  the company expended million  million  and million  respectively  on research and development activities 
increases in research and development spending were primarily attributable to expanded preclinical development of the company s research programs which included the manufacturing product development for the company s c inhibitor and apogen product candidates and the initiation of clinical trials following authorization by the fda of the company s ind for its lead c inhibitor product candidate 
see item business alexion s drug development programs  cardiopulmonary bypass surgery 
the company s general and administrative expenses were million  million  and million for the fiscal years ended july   and  respectively 
the increase in general and administrative expenses in fiscal consisted of  related to increased expenses associated with facilities expansion  employee benefits  and increased travel and administrative costs attributable to increased clinical  regulatory  and scientific conference activities 
the remaining balance  of the increase was related to increased costs for outside professional services and insurance related to business development  recruiting  patent and legal activities as a public company 
other income expense  net  representing primarily net investment income expenses  was   and  for the fiscal years ended july    and  respectively 
this fluctuation over the past three years was due primarily to greater investment income from higher cash balances available for investment and a more favorable investment market during fiscal year as compared to the prior two fiscal years 
as a result of the above factors  the company had incurred net losses of million  million  and million for the fiscal years ended july   and  respectively 
liquidity and capital resources since its inception through july   the company has financed its operations and capital expenditures primarily through its private placements and initial public offering of equity securities resulting in approximately million of aggregate net proceeds 
the company has financed the purchase of certain equipment through million of secured notes payable to a financing institution and  of capital lease obligations 
through july   the company has also received approximately million in research and development support under its collaborations with us surgical and gti novartis 
the company has also received million from its sbir grants from the nih and  under the atp grant from nist 
all of the foregoing proceeds have been used to fund operating activities of approximately million and investments of approximately million and  in equipment and licensed technology rights and patents  respectively  through july  as of july   the company had working capital of approximately million and total cash  cash equivalents  and marketable securities amounted to approximately million 
the company increased its cash and cash equivalents by million during the twelve months ended july  this increase resulted principally from cash flows provided by i financing activities which provided million from the net proceeds received from the issuance of common stock and  from the return of security deposits offset by  in repayments of notes payable and ii investing activities which generated million from the net proceeds of maturing marketable securities offset by equipment purchases of  these cash inflows were offset by the million cash outflow used in operating activities primarily as a result of million of operating losses 
at july   approximately million of cash is held in short term highly liquid investments with original maturities of less than three months 
subsequent to the company s fiscal year end on july   the company received the following significant additional proceeds 
in september  the company received approximately million in net proceeds from the issuance of shares of series b preferred stock to a single institutional investor 
at the end of september  us surgical and the company modified the july joint development agreement 
as part of the modification  us surgical made an additional million payment to the company for equity  exclusive licensing rights  and certain manufacturing assets 
see item strategic alliances  collaborations and licenses united states surgical corporation 
see item market for registrant s common equity and related stockholder matters recent sale of unregistered securities 
the company leases its administrative and research and development facilities under three operating leases expiring in june  december and march each with a renewal option for up to an additional three years 
the company is obligated to make payments pursuant to certain of its licensing and research and development agreements 
the company is scheduled to pay   and  assuming no termination of these agreements during the fiscal years ending july   and  respectively 
in addition  the company is obligated to make certain future milestone payments  aggregating up to  to certain of its licensors  with regards to receiving regulatory approval on the company s anticipated ind filings as well as upon certain patent issuances 
see item business strategic alliances  collaborations and licenses 
the company anticipates that its existing available capital resources and interest earned on available cash and marketable securities should be sufficient to fund its operating expenses and capital requirements as currently planned for at least the next eighteen months 
while the company currently has no material commitments for capital expenditures  the company s future capital requirements will depend on many factors  including the progress of the company s research and development programs  progress in clinical trials  the time and costs involved in obtaining regulatory approvals  the costs involved in obtaining and enforcing patents and any necessary licenses  the ability of the company to establish development and commercialization relationships  and the costs of manufacturing scale up 
see item business alexion s drug development strategy 
the company expects to incur substantial additional costs  including costs associated with research  preclinical and clinical testing  manufacturing process development  and additional capital expenditures associated with facility expansion and manufacturing requirements in order to commercialize its products currently under development 
the company will need to raise substantial additional funds through additional financings including public or private equity offerings and collaborative research and development arrangements with corporate partners 
there can be no assurance that funds will be available on terms acceptable to the company  if at all  or that discussions with potential collaborative partners will result in any agreements 
the unavailability of additional financing could require the company to delay  scale back or eliminate certain of its research and product development programs or to license third parties to commercialize products or technologies that the company would otherwise undertake itself  any of which could have a material adverse effect on the company 
as of july   the company had approximately million and million of net operating loss and tax credit carryforwards for tax reporting purposes  respectively  which expire commencing in fiscal the tax reform act of the tax act contains certain provisions that may limit the company s ability to utilize net operating loss and tax credit carryforwards in any given year if certain events occur  including cumulative changes in ownership interests in excess of over a three year period 
there can be no assurance that ownership changes in future periods will not significantly limit the company s use of its existing net operating loss and tax credit carryforwards 

